Vosoritide is a linear growth promoting drug specifically used to treat children with achondroplasia and open epiphyses. Its main ingredient, Vosoritide, targets a specific target, NPRB, and is administered by subcutaneous injection. This article will discuss the main indications, applicable populations, and contraindications of Vosoritide.
Indications of Vosoritide
Vosoritide is designed to promote linear growth in children with achondroplasia whose epiphyses have not yet closed.
Promote linear growth in children with achondroplasia
These patients cannot grow normally due to abnormal bone growth plates. Vosoritide works by stimulating these growth plates to help patients achieve more normal height growth. Therefore, for children with such conditions, Vosoritide provides a new treatment option.
By activating the NPRB target, Vosoritide can effectively promote linear growth, bringing hope to children who are limited by achondroplasia.
Applicable population of Vosoritide
For pediatric patients who meet specific conditions, Vosoritide can not only promote their linear growth, but also improve their quality of life.
Pediatric patients
The safety and efficacy of Vosoritide have been verified in pediatric patients, especially those with achondroplasia and open epiphyses. This group can observe significant growth improvement after using Vosoritide. Before starting treatment, doctors need to adjust the dose according to the patient's weight to clarify safe and effective medication.
Patients with renal dysfunction
Although the effect of Vosoritide on patients with renal dysfunction has not been fully evaluated, no dose adjustment is required for patients with glomerular filtration rate (eGFR)≥ 60ml/min/1.73m2. This suggests that some patients with renal dysfunction may also benefit from Vosoritide treatment, but patients with eGFR < 60mL/min/1.73m2 are not recommended.
Understanding renal function status is important to determine whether Vosoritide is suitable for a specific individual and helps avoid potential risks.
Contraindications of Vosoritide
Given the risk of hypotension, individuals with cardiovascular problems should carefully consider whether Vosoritide is a treatment option.
Patients with cardiovascular disease
In clinical studies, Vosoritide may cause a transient drop in blood pressure, so Vosoritide should be used with caution in patients with significant heart or vascular disease. These patients may not be suitable for Vosoritide treatment to avoid adverse reactions.
Pregnant and breastfeeding women
There is currently a lack of safety data on the use of Vosoritide in pregnant and breastfeeding women, which means that these two groups of people should follow their doctor's advice when using Vosoritide and weigh the potential risks and benefits. Especially during pregnancy, the use of any drug needs to be carefully evaluated.
Given the limited information available, pregnant and breastfeeding women should consult a professional doctor before using Vosoritide to protect the health of mother and baby.
